Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuria

Kidney International

Volumn 57, Issue 2, 2000, Pages 385-400

  Raats, C J Ilse ^a   Van Den Born, Jacob ^a   Berden, Jo H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Extracellular matrix; Glomerular basement membrane; Heparan sulfate proteoglycans; Podocytes; Protein permeability

Indexed keywords

AGRIN; PROTEOHEPARAN SULFATE;

DEPOLYMERIZATION; DIABETIC NEPHROPATHY; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HEYMANN NEPHRITIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANE PERMEABILITY; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; STREPTOZOCIN DIABETES;

EID: 0033946278     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00858.x     Document Type: Article

References (220)

1. 1. DWORKIN LD, BRENNER BM: Biophysical basis of glomerular filtration, in The Kidney: Physiology and Pathophysiology, edited by SELDIN DW, GIEBISCH G, New York, Raven Press, 1992, p 979
2. 2. ADLER S, SHARMA R, SAVIN VJ, ABBI R, ENG B: Alteration of glomerular permeability to macromolecules induced by cross-linking of beta-1 integrin receptors. Am J Pathol 149:987-996, 1996
3. 3. LAURENS W, BATTAGLIA C, FOGLIENI C, DE VOS R, MALANCHINI B, VAN DAMME BJC, VANRENTERGHEM YF, REMUZZI G, REMUZZI A: Direct podocyte damage in the single nephron leads to albuminuria in vivo. Kidney Int 47:1078-1086, 1995
4. 4. ORIKASA M, MATSUI K, OITE T, SHIMIZU F: Massive proteinuria in rats by a single intravenous injection of a monoclonal antibody. J Immunol 141:807-814, 1988
5. 5. KAWACHI H, MATSUI K, ORIKASA M, MORIOKA T, OITE T, SHIMIZU F: Quantitative studies of monoclonal antibody 5-1-6-induced proteinuric state in rats. Clin Exp Immunol 87:215-219, 1992
6. 6. CHANG RL, UEKI IF, TROY JL, DEEN WM, ROBERTSON CR, BRENNER BM: Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in rats using neutral dextran. Biophys J 15:887-906, 1975
7. 7. BOHRER MP, BAYLIS C, HUMES HD, GLASSOCK RJ, ROBERTSON CR, BRENNER BM: Permselectivity of the glomerular capillary wall. Facilitated filtration of circulating polycations. J Clin Invest 61:72-78, 1978
8. 8. CHANG RL, DEEN WM, ROBERTSON CR, BRENNER BM: Permselectivity of the glomerular capillary wall. III. Restricted transport of polyanions. Kidney Int 8:212-218, 1975
9. 9. YURCHENKO PD, SCHITTNY JC: Molecular architecture of basement membranes. FASEB J 4:1577-1590, 1990
10. 10. INOUE S: Ultrastructure of basement membranes. Int Rev Cytol 117:57-97, 1989
11. 11. MINER JH: Developmental biology of glomerular basement membrane components. Curr Opin Nephrol Hypertens 7:13-19, 1998
12. 12. KANWAR YS, FARQUHAR MG: Isolation of glycosaminoglycans (heparan sulfate) from glomerular basement membranes. Proc Natl Acad Sci USA 76:4493-4497, 1979
13. 13. KANWAR YS, FARQUHAR MG: Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci USA 76:1303-1307, 1979
14. 14. GROFFEN AJA, RUEGG MA, DIJKMAN HBPM, VAN DER VELDEN TJ, BUSKENS CA, VAN DEN BORN J, ASSMANN KJM, MONNENS LAH, VEERKAMP JH, VAN DEN HEUVEL LPWJ: Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 46:19-27, 1998
15. 15. RAATS CJI, BAKKER MAH, HOCH W, TAMBOER WPM, GROFFEN AJA, VAN DEN HEUVEL LPWJ, BERDEN JHM, VAN DEN BORN J: Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 273:17832-17838, 1998
16. 16. HALFTER W, DONG S, SCHURER B, COLE GJ: Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273:25404-25412, 1998
17. 17. SAARELA J, REHN M, OIKARINEN A, AUTIO HARMAINEN H, PIHLAJANIEMI T: The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 153:611-626, 1998
18. 18. MURDOCH AD, DODGE GR, COHEN I, TUAN RS, IOZZO RV: Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan): A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem 267:8544-8557, 1992
19. 19. KALLUNKI P, TRYGGVASON K: Human basement membrane heparan sulfate proteoglycan core protein: A 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Cell Biol 116:559-571, 1992
20. 20. NOONAN DM, FULLE A, VALENTE P, CAI S, HORIGAN EA, SASAKI M, YAMADA Y, HASSELL JR: The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266:22939-22947, 1991
21. 21. GROFFEN AJ, BUSKENS CA, VAN KUPPEVELI TH, VEERKAMP JH, MONNENS LA, VAN DEN HEUVEL LP: Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. Eur J Biochem 254:123-128, 1998
22. 22. RUPP F, PAYAN DG, MAGILL-SOLC C, COWAN DM, SCHELLER RH: Structure and expression of a rat agrin. Neuron 6:811-823, 1991
23. 23. TSEN G, HALFTER W, KROGER S, COLF GJ: Agrin is a heparan sulfate proteoglycan. J Biol Chem 270:3392-3399, 1995
24. 24. DODGE GR, KOVALSZKY I, CHU ML, HASSELL JR, MCBRIDE OW, YI HF, IOZZO RV: Heparan sulfate proteoglycan of human colon: Partial molecular cloning, cellular expression, and mapping of the gene (HSPG2) to the short arm of human chromosome I. Genomics 10:673-680, 1991
25. 25. KALLUNKI P, EDDY RL, BYERS MG, KESTILA M, SHOWS TB, TRYGGVASON K: Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 1p36.1-p35and identification of a BamHI restriction fragment length polymorphism. Genomics 11:389-396, 1991
26. 26. RUPP F, OZCELIK T, LINIAL M, PETERSON K, FRANCKE U, SCHELLER RH: Structure and chromosomal localization of the mammalian agrin gene. J Neurosci 12:3535-3544, 1992
27. 27. OH SP, WARMAN ML, SELDIN MF, CHENG SD, KNOLL JH, TIMMONS S, OLSEN BR: Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1 (XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 19:494-499, 1994
28. 28. PAULSSON M, YURCHENKO PD, RUBEN GC, ENGEL J, TIMPL R: Structure of low density heparan sulfate proteoglycan isolated from a mouse tumor basement membrane. J Mol Biol 197:297-313, 1987
29. 29. DENZER AJ, SCHULTHESS T, FAUSER C, SCHUMACHER B, KAMMERER RA, ENGEL J, RUEGG MA: Electron miscroscopic structure of agrin and mapping of its binding site in laminin-1. EMBO J 17:335-343, 1998
30. 30. OH SP, KAMAGATA Y, MURAGAKI Y, TIMMONS S, OOSHIMA A, OLSEN BR: Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91:4229-4233, 1994
31. 31. SAARELA J, YLIKARPPA R, REHN M, PURMONEN S, PIHLAJANIEMI T: Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16:319-328, 1998
32. 32. REHN M, PIHLAJANIEMI T: Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci USA 91:4234-4238, 1994
33. 33. YAMANE Y, YAOITA H, COUCHMAN JR: Basement membrane proteoglycans are of epithelial origin in rodent skin. J Invest Dermatol 106:531-537, 1996
34. 34. NOONAN DM, HASSELL JR: Perlecan, the large low-density proteoglycan of basement membranes: Structure and variant forms. Kidney Int 43:53-60, 1993
35. 35. ABE N, MURAGAKI Y, YOSHIOKA H, INOUE H, NINOMIYA Y: Identification of a novel collagen chain represented by extensive interruptions in the triple-helical region. Biochem Biophys Res Commun 196:576-582, 1993
36. 36. LINDAHL U, LIDHOLT K, SPILLMANN D, KJELLEN L: More to "heparin" than anticoagulation. Thromb Res 75:1-32, 1994
37. 37. TURNBULL JE, GALLAGHER JT: Molecular organization of heparan sulphate from human skin fibroblasts. Biochem J 265:715-724, 1990
38. 38. LINDBLOM A, BENGTSSON OLIVECRONA G, FRANSSON LA: Domain structure of endothelial heparan sulphate. Biochem J 279:821-829, 1991
39. 39. SCHMIDT A, LEMMING G, YOSHIDA K, BUDDECKE E: Molecular organization and antiproliferative domains of arterial tissue heparan sulfate. Eur J Cell Biol 59:322-328, 1992
40. 40. LYON M, DEAKIN JA, GALLAGHER JT: Liver heparan sulfate structure: A novel molecular design. J Biol Chem 269:11208-11215, 1994
41. 41. HISCOCK DR, CANFIELD A, GALLAGHER JT: Molecular structure of heparan sulphate synthesised by bovine aortic endothelial cells. Biochim Biophys Acta 1244:104-112, 1995
42. 42. MACCARANA M, SAKURA Y, TAWADA A, YOSHIDA K, LINDAHL U: Domain structure of heparan sulfates from bovine organs. J Biol Chem 271:17804-17810, 1996
43. 43. LINDAHL U, THUNBERG L, BACKSTROM G. RIESENFELD J, NORDLING K, BJORK I: Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 259:12368-12376, 1984
44. 44. KJELLEN L, LINDAHL U: Proteoglycans: Structures and interactions. Annu Rev Biochem 60:443-475, 1991
45. 45. MACCARANA M, CASU B, LINDAHL U: Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 268:23898-23905, 1993
46. 46. TURNBULL JE, FERNIG DG, KE Y, WILKINSON MC, GALLAGHER JT: Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267:10337-10341, 1992
47. 47. BULLOCK SL, FLETCHER JM, BEDDINGTON RSP, WILSON VA: Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 12:1894-1906, 1998
48. 48. FARQUHAR MG, LEMKIN MC, STOW JL: Role of proteoglycans in glomerular function and pathology, in Nephrology, edited by ROBINSON RR, New York, Springer-Verlag, 1985, p 580
49. 49. KANWAR YS, LIU ZZ, KASHIHARA N, WALLNER EI: Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 11:390-413, 1991
50. 50. KANWAR YS, LINKER A, FARQUHAR MG: Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86:680-693, 1980
51. 51. ROSENZWEIG LJ, KANWAR YS: Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125-I-bovine serum albumin. Lab Invest 47:177-184, 1982
52. 52. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, BERDEN JHM: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
53. 53. COTRAN RS, RENNKE HG: Anionic sites and the mechanisms of proteinuria. (editorial) N Engl J Med 309:1050-1052, 1983
54. 54. WADA N, UEDA Y, IIDAKA K, INAGE Z, KIKKAWA Y, KITAGAWA T: Portions of basement membrane with decreased negative charge in various glomerulonephritis. Clin Nephrol 34:9-16, 1990
55. 55. SASAKI M, BATSFORD S, THAISS F, OITE T, VOGT A: Ultrastructural studies in passive in situ immune complex glomerulonephritis: A rat model for membranous glomerulonephritis. Virchows Arch B Cell Pathol Incl Mol Pathol 58:173-180, 1989
56. 56. WASHIZAWA K, KASAI S, MORI T, KOMIYAMA A, SHIGEMATSU H: Ultrastructural alteration of glomerular anionic sites in nephrotic patients. Pediatr Nephrol 7:1-5, 1993
57. 57. DUAN HJ, NAKAZAWA K, ISHIGAME H, ITOH N, SHIGEMATSU H: Masking of anionic sites by deposits in lamina rara externa in immune complex nephritis in rats. Virchows Arch B Cell Pathol Incl Mol Pathol 60:165-171, 1991
58. 58. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, WEENING JJ, BERDEN JHM: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 43:454-463, 1993
59. 59. VAN BRUGGEN MCJ, KRAMERS K, HYLKEMA MN, VAN DEN BORN J, BAKKER MAH, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Decrease of heparan sulfate in the glomerular basement membrane in murine lupus nephritis. Am J Pathol 146:753-763, 1995
60. 60. TAMSMA JT, VAN DEN BORN J, BRUTJN JA, ASSMANN KJM, WEENING JJ, BERDEN JHM, WIELANDER J, SCHRAMA E, HERMANS J, VEERKAMP JH, LEMKES HHPJ, VAN DEN WOUDE FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37:313-320, 1994
61. 61. RAATS CJI, BAKKER MAH, VAN DEN BORN J, BERDEN JHM: Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 272:26734-26741, 1997
62. 62. DENZER AJ, GESEMANN M, SCHUMACHER B, RUEGG MA: An amino-terminal extension is required for the secretion of chick agrin and its binding to extracellular matrix. J Cell Biol 131:1547-1560, 1995
63. 63. DENZER AJ, BRANDENBERGER R, GESEMANN M, CHIQUET M, RUEGG MA: Agrin binds to the nerve-muscle basal lamina via laminin. J Cell Biol 137:671-683, 1997
64. 64. GROFFEN AJA, YARD B, VAN DEN BORN J, BERDEN JHM, VAN DER WOUDE FJ, EIGENHUIJSEN J, BUSKENS CA, VEERKAMP JH, MONNENS LAH, VAN DEN HEUVEL LPWJ: Functional analysis of human renal agrin. J Biol Chem (in press)
65. 65. COLOGNATO H, MACCARRICK M, O'REAR JJ, YURCHENKO PD: The laminin alpha-2-chain short arm mediates cell adhesion through both the alpha-1-beta-1 and alpha-2-beta-1 integrins. J Biol Chem 272:29330-29336, 1997
66. 66. SALMIVIRTA M, LIDHOLT K, LINDAHL U: Heparan sulfate: A piece of information. FASEB J 10:1270-1279, 1996
67. 67. KANWAR YS, ROSENZWEIG LJ: Clogging of the glomerular basement membrane. J Cell Biol 93:489-494, 1982
68. 68. COFFEY AK, KARNOVSKY MJ: Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 120:248-255, 1985
69. 69. FARBER JL, KYLE ME, COLEMAN JB: Mechanisms of cell injury by activated oxygen species. Lab Invest 62:670-679, 1990
70. 70. CADENAS E: Biochemistry of oxygen toxicity. Annu Rev Biochem 58:79-110, 1989
71. 71. WANG A, FAN MY, TEMPLETON DM: Growth modulation and proteoglycan turnover in cultured mesangial cells. J Cell Physiol 159:295-310, 1994
72. 72. VAN DEN BORN J, VAN DEN HEUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, BERDEN JHM: Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: Characterization and immunohistological application in human tissues. J Histochem Cytochem 42:89-102, 1994
73. 73. VAN DEN BORN J, GUNNARSSON K, BAKKER MAH, KJELLEN L, KUSCHE-GULLBERG M, MACCARANA M, BERDEN JHM, LINDAHL U: Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 270:31303-31309, 1995
74. 74. BERDEN JH: Lupus nephritis. Kidney Int 52:538-558, 1997
75. 75. FAABER P, RIJKE TP, VAN DE PUTTE LB, CAPEL PJ, BERDEN JH: Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate: The major glycosaminoglycan in glomerular basement membranes. J Clin Invest 77:1824-1830, 1986
76. 76. EILAT D: Cross-reactions of anti-DNA antibodies and the central dogma of lupus nephritis. Immunol Today 6:123-127, 1986
77. 77. TERMAAT RM, BRINKMAN K, VAN GOMPEL F, VAN DEN HEUVEL LP, VEERKAMP JH, SMEENK RJ, BERDEN JH: Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J Autoimmun 3:531-545, 1990
78. 78. KRAMERS C, HYLKEMA MN, VAN BRUGGEN MCJ, VAN DE LANGEMAAT R, DIJKMAN HBPM, ASSMANN KJM, SMEENK RJT, BERDEN JHM: Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94:568-577, 1994
79. 79. SCHMIEDEKE TM, STOCKL FW, WEBER R, SUGISAKI Y, BATSFORD SR, VOGT A: Histones have high affinity for the glomerular basement membrane: Relevance for immune complex formation in lupus nephritis. J Exp Med 169:1879-1894, 1989
80. 80. VAN BRUGGEN MC, WALGREEN B, RIJKE TP, TAMBOER W, KRAMERS K, SMEENK RJ, MONESTIER M, FOURNIE GJ, BERDEN JH: Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 27:1564-1569, 1997
81. 81. VAN BRUGGEN MCJ, WALGREEN B, RIJKE GPM, CORSIUS MJAMM, ASSMANN KJM, SMEENK RJT, VAN DEDEM GWK, KRAMERS C, BERDEN JHM: Heparin and heparinoids present the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int 50:1555-1564, 1996
82. 82. KASHIHARA N, MAKINO H, SZEKANECZ Z, WALTENBAUGH CR, KANWAR YS: Nephritogenicity of anti-proteoglycan antibodies in experimental murine lupus nephritis. Lab Invest 67:752-760, 1992
83. 83. VAN BRUGGEN MC, KRAMERS C, HYLKEMA MN, SMEENK RJ, BERDEN JH: Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis: A longitudinal study on plasma and glomerular eluates in MRL/ lpr mice. Clin Exp Immunol 105:132-139, 1996
84. 84. VAN BRUGGEN MCJ, KRAMERS C, WALGREEN B, ELEMA JD, KAILENBERG CGM, VAN DEN BORN J, SMEENK RJT, ASSMANN KJM, MULLER S, MONESTIER M, BERDEN JHM: Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 12:57-66, 1997
85. 85. MELNICK GF, LADOULIS CT, CAVALLO T: Decreased anionic groups and increased permeability precedes deposition of immune complexes in the glomerular capillary wall. Am J Pathol 105:114-120, 1981
86. 86. KELLEY VE, CAVALLO T: Glomerular permeability: Focal loss of anionic sites in glomeruli of proteinuric mice with lupus nephritis. Lab Invest 42:59-64, 1980
87. 87. CAMUSSI G, TETTA C, SEGOLONI G, CODA R, VERCELLONE A: Localization of neutrophil cationic proteins and loss of anionic charges in glomeruli of patients with systemic lupus erythematosus glomerulonephritis. Clin Immunol Immunopathol 24:299-314, 1982
88. 88. CAMUSSI G, TETTA C, MAZZUCCO G, MONGA G, ROFFINELLO C, ALBERTON M, DELLABONA P, MALAVASI F, VERCELLONE A: Platelet cationic proteins are present in glomeruli of lupus nephritis patients. Kidney Int 30:555-565, 1986
89. 89. GHIGGERI GM, BERTELLI R, GINEVRI F, OLEGGINI R, ALTIERI P, TRIVELLI A, GUSMANO R: Multiple mechanisms for doxorubicin cytotoxicity on glomerular epithelial cells "in vitro." Eur J Pharmacol 228:77-83, 1992
90. 90. KAWAGUCHI M, YAMADA M, WADA H, OKIGAKI T: Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. Toxicology 72:329-340, 1992
91. 91. GREIBER S, MUNZEL T, KASTNER S, MULLER B, SCHOLLMEIER P, PAVENSTADT H: NAD(P)H oxidase activity in cultured human podocytes: Effects of adenosine triphosphate. Kidney Int 53:654-663, 1998
92. 92. BAUD L, HAGEGE J, SRAER J, RONDEAU E, PEREZ J, ARDAILLOU R: Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity. J Exp Med 158:1836-1852, 1983
93. 93. ADLER S, BAKER PJ, JOHNSON RJ, OCHI RF, PRITZL P, COUSER WG: Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77:762-767, 1986
94. 94. SEDOR JR, CAREY SW, EMANCIPATOR SN: Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. J Immunol 138:3751-3757, 1987
95. 95. RADEKE HH, MEIER B, TOPLEY N, FLOEGE J, HABERMEHI GG, RESCH K: Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 37:767-775, 1990
96. 96. TAN S, YOKOYAMA Y, DICKENS E, CASH TG, FREEMAN BA, PARKS DA: Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med 15:407-414, 1993
97. 97. TAY M, COMPER WD, VASSILIOU P, GLASGOW EF, BAKER MS, PRATT L: The inhibitory action of oxygen radical scavengers on proteinuria and glomerular heparan sulfate loss in the isolated perfused kidney. Biochem Int 20:767-778, 1990
98. 98. FREEMAN BA, CRAPO JD: Biology of disease: Free radicals and tissue injury. Lab Invest 47:412-426, 1982
99. 99. CROSS CE, HALLIWELL B, BORISH ET, PRYOR WA, AMES BN, SAUL RL, MCCORD JM, HARMAN D: Oxygen radicals and human disease. (clinical conference) Ann Intern Med 107:526-545, 1987
100. 100. JOHNSON RJ, LOVETT D, LEHRER RI, COUSER WG, KLEBANOFF SJ: Role of oxidants and proteases in glomerular injury. Kidney Int 45:352-359, 1994
101. 101. ISCHIROPOULOS H, ZHU L, BECKMAN JS: Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 298:446-451, 1992
102. 102. ISCHIROPOULOS H, ZHU L, CHEN J, TSAI M, MARTIN JC, SMITH CD, BECKMAN JS: Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298:431-437, 1992
103. 103. RADI R, BECKMAN JS, BUSH KM, FREEMAN BA: Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:481-487, 1991
104. 104. DILEEPAN KN, SHARMA R, STECHSCHULTE DJ, SAVIN VJ: Effect of superoxide exposure on albumin permeability of isolated rat glomeruli. J Lab Clin Med 121:797-804, 1993
105. 105. MCCARTHY ET, SHARMA R, SHARMA M, LI JZ, GE X-L, DILEEPAN KN, SAVIN VJ: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9:433-438, 1998
106. 106. YOSHIOKA T, ICHIKAWA I, FOGO A: Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2:902-912, 1991
107. 107. MILNER LS, WEI SH, HOUSER MT: Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. J Lab Clin Med 118:427-434, 1991
108. 108. OKASORA T, TAKIKAWA T, UTSUNOMIYA Y, SENOH I, HAYASHIBARA H, SHIRAKI K, KASAGI T, SHIMIZU F: Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron 60:199-203, 1992
109. 109. DIAMOND JR, BONVENTRE JV, KARNOVSKY MJ: A role for oxygen free radicals in aminonucleoside nephrosis. Kidney Int 29:478-483, 1986
110. 110. RICARDO SD, BERTRAM JF, RYAN GB: Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 4:1974-1986, 1994
111. 111. THAKUR V, WALKER PD, SHAH SV: Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria. Kidney Int 34:494-499, 1988
112. 112. SHAH SV: Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 254:F337-F344, 1988
113. 113. BALIGA R, UEDA N, SHAH SV: Kidney iron status in passive Heymann nephritis and the effect of an iron-deficient diet. J Am Soc Nephrol 7:1183-1188, 1996
114. 114. REHAN A, JOHNSON KJ, WIGGINS RC, KUNKEL RG, WARD PA: Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest 51:396-403, 1984
115. 115. FEITH GW, ASSMANN KJM, BOGMAN MJJT, VAN GOMPEI APM, SCHALKWIJK J, KOENE RAP: Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice. Nephrol Dial Transplant 11:599-607, 1996
116. 116. COCHRANE SM, BYRNE JC, ROBINSON GB: The permselectivity of glomerular basement membrane can be compromised by glycation or by exposure to low levels of hypochlorite. Biochim Biophys Acta 1361:217-228, 1997
117. 117. SHAH SV, BARICOS WH, BASCI A: Degradation of human glomerular basement membrane by stimulated neutrophils: Activation of a metalloproteinase(s) by reactive oxygen metabolites. J Clin Invest 79:25-31, 1987
118. 118. LI JZ, SHARMA R, DILEEPAN KN, SAVIN VJ: Polymorphonuclear leukocytes increase glomerular albumin permeability via hypohalous acid. Kidney Int 46:1025-1030, 1994
119. 119. JOHNSON RJ, COUSER WG, CHI EY, ADLER S, KLEBANOFF SJ: New mechanism for glomerular injury: Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79:1379-1387, 1987
120. 2-halide system in immune complex nephritis. Kidney Int 32:342-349, 1987
121. 121. HEERINGA P, VAN GOOR H, MOSHAGE H, KLOK PA, HUTTEMA MG, DE JAGER A, SCHEP AJ, KALLENBERG CGM: Expression of iNOS, eNOS and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int 53:382-393, 1998
122. 122. BERTANI T, POGGI A, POZZONI R, DELAINI F, SACCHI G, THOUA Y, MECCA G, REMUZZI G, DONATI MB: Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 46:16-23, 1982
123. 123. DESASSIS JF, RAATS CJI, BAKKER MAH, VAN DEN BORN J, BERDEN JHM: Anti-proteinuric effect of cyclosporin A in adriamycin nephropathy in rats. Nephron 75:336-341, 1997
124. 124. FIEGELSON EB, DRAKE JW, RECANT L: Experimental aminonucleoside nephrosis in rats. J Lab Clin Med 50:437-446, 1957
125. 125. DAVIES KJA, DOROSHOW JH: Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261:3060-3067, 1986
126. 126. DOROSHOW JH, DAVIES KJA: Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 261:3068-3074, 1986
127. 127. BARBEY M, FELS LM, SOOSE M, POELSTRA K, GWINNER W, BAKKER WW, STOLTE H: Adriamycin affects glomerular renal function: Evidence for the involvement of oxygen radicals. Free Radic Res Commun 7:195-203, 1989
128. 128. NEALE TJ, ULLRICH R, OJHA P, POCZEWSKI H, VERHOEVEN AJ, KERJASCHKI D: Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 90:3645-3649, 1993
129. 129. KASHIHARA N, WATANABE Y, MAKINO H, WALLNER EI, KANWAR YS: Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309-6313, 1992
130. 130. PANASYUK A, FRATI E, RIBAUFT D, MITROVIC D: Effect of reactive oxygen species on the biosynthesis and structure of newly synthesized proteoglycans. Free Radic Biol Med 16:157-167, 1994
131. 131. MOSELEY R, WADDINGTON R, EVANS P, HALLIWELL B, EMBERY G: The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim Biophys Acta 1244:245-252, 1995
132. 2-chloride system. Am J Pathol 143:907-917, 1993
133. 133. LIU Z, PERLIN AS: Evidence of a selective free radical degradation of heparin, mediated by cupric iron. Carbohydr Res 255:183-191, 1994
134. 134. NAGASAWA K, UCHIYAMA H, SATO N, HATANO A: Chemical change involved in the oxidative-reductive depolymerization of heparin. Carbohydr Res 236:165-180, 1992
135. 135. METCALFE DD, THOMPSON HL, KLEBANOFF SJ, HENDERSON WR: Oxidative degradation of rat mast-cell heparin proteoglycan. Biochem J 272:51-57, 1990
136. 136. VOLPI N, MASCELLANI G, BIANCHINI P: Low molecular weight heparins (5 kDa) and oligoheparins (2kDa) produced by gel permeation enrichment or radical process: Comparison of structures and physicochemical and biological properties. Anal Biochem 200:100-107, 1992
137. 137. VAN DEN BORN J, JANN K, ASSMANN KJM, LINDAHL U, BERDEN JHM: N-acetylated domains in heparan sulfates revealed by a monoclonal antibody against Escherichia coli K5 capsular polysaccharide. J Biol Chem 271:22802-22809, 1996
138. 35S]heparan sulfate. Biochem Int 19:1241-1251, 1989
139. 139. RADI R, RUBBO H, BUSH K, FREEMAN BA: Xanthine oxidase binding to glycosaminoglycans: Kinetics and superoxide interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339:125-135, 1997
140. 140. ADACHI T, FUKUSHIMA T, USAMI Y, HIRANO K: Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem J 289:523-527, 1993
141. 141. VILAR RE, GHAEL D, LI M, BHAGAI DD, ARRIGO LM, COWMAN MK, DWECK HS, ROSENFELD L: Nitric oxide degradation of heparin and heparan sulphate. Biochem J 324:473-479, 1997
142. 142. LI M, ROSENFELD L, VILAR RE, COWMAN MK: Degradation of hyaluronan by peroxynitrite. Arch Biochem Biophys 341:245-250, 1997
143. 143. SAARI H, KONTTINEN YT, FRIMAN C, SORZA T: Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate. Inflammation 17:403-415, 1993
144. 144. SATO H, TAKAHASHI T, IDE H, FUKUSHIMA T, TABATA M, SEKINE F, KOBAYASHI K, NEGISHI M, NIWA Y: Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid: Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum 31:63-71, 1988
145. 145. HIEBERI LM, LIU JM: Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 83:47-51, 1990
146. 146. MYRUP B, HANSEN PM, JENSEN T, KOFOED-ENEVOLDSEN A, FELDT-RASMUSSEN B, GRAM J, KLUFI C, JESPERSEN J, DECKERT T: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345:421-422, 1995
147. 147. VAN DER PIJL JW, VAN DER WOUDE FJ, GEELHOED DUIJVESTIJN PH, FROLICH M, VAN DER MEER FJ, LEMKES HH, VAN ES LA: Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol 8:456-462, 1997
148. 148. GAMBARO G, VENTURINI AP, NOONAN DM, FRIES W, RE G, GARBISA S, MILANESI C, PESARINI A, BORSATTI A, MARCHI E, BAGGIO B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46:797-806, 1994
149. 149. GAMBARO G, CAVAZZANA AO, LUZI P, PICCOLI A, BORSATTI A, CREPALDI G, MARCHI E, VENTURINI AP, BAGGIO B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42:285-291, 1992
150. 150. CHEN ZY, JIANG XY, FEI L: Effect of heparin on the anionic sites of glomerular basement membrane in adriamycin nephrosis in rats. Chin Med J 105:671-675, 1992
151. 151. JOHNSON RJ, COUSER WG, ALPERS CE, VISSERS M, SCHULZE M, KLEBANOFF SJ: The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. J Exp Med 168:1169-1174, 1988
152. 152. SCHRIJVER G, SCHALKWIJK J, ROBBEN JCM, ASSMANN KJM, KOENE RAP: Antiglomerular basement membrane nephritis in beige mice. J Exp Med 169:1435-1448, 1989
153. 153. HEERINGA P, VAN DEN BORN J, BROUWER E, DULMAN KM, KLOK PA, HUITEMA MG, LIMBURG PC, BAKKER MAH, BERDEN JHM, DAHA MR, KALLENBERG CGM: Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo refusion in rats. Clin Exp Immunol 105:321-329, 1996
154. 154. VAN DE LEST CH, VERSTEEG EM, VEERKAMP JH, VAN KUPPEVELT TH: Digestion of proteoglycans in porcine pancreatic elastase-induced emphysema in rats. Eur Respir J 8:238-245, 1995
155. 155. KEY NS, PLATT JL, VERCELLOTTI GM: Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler Thromb 12:836-842, 1992
156. 156. SUZUKI S, GEJYO F, KURODA T, KAZAMA JJ, IMAI N, KIMURA H, ARAKAWA M: Effects of a novel elastase inhibitor, ONO-5046, on nephrotoxic serum nephritis in rats. Kidney Int 53:1201-1208, 1998
157. 157. MATZNER Y, BAR-NER M, YAHALOM J, ISHAI-MICHAELI R, FUKS Z, VLODAVSKY I: Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils: Possible role in invasion through basement membranes. J Clin Invest 76:1306-1313, 1985
158. 158. YAHALOM J, ELDOR A, FUKS Z, VLODAVSKY I: Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 74:1842-1849, 1984
159. 159. SAVION K, VLODAVSKY I, FUKS Z: Interaction of T lymphocytes and macrophages with cultured vascular endothelial cells: attachment, invasion, and subsequent degradation of the subendothelial extra-cellular matrix. J Cell Physiol 118:169-178, 1984
160. 160. VLODAVSKY I, ELDOR A, HAIMOVITZ-FRIEDMAN A, MATZNER Y, ISHAI-MICHAELI R, LIDER O, NAPARSTEK Y, COHEN IR, FUKS Z: Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112-127, 1992
161. 161. SEWELL RF, BRENCHLEY PE, MALLICK NP: Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate. Biochem J 264:777-783, 1989
162. 162. BASHKIN P, RAZIN E, ELDOR A, VLODAVSKY I: Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 75:2204-2212, 1990
163. 163. BENEZRA M, VLODAVSKY I, BAR-SHAVII R: Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase. Exp Cell Res 201:208-215, 1992
164. 164. BAR-NER M, MAYER M, SCHIRRMACHER V, VLODAVSKY I: Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J Cell Physiol 128:299-306, 1986
165. 165. VAN KUPPEVELT TH, VEERKAMP JH: Application of cationic probes for the ultrastructural localization of proteoglycans in basement membranes. Microsc Res Tech 28:125-140, 1994
166. 166. TEMPLETON DM: Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes. Lab Invest 61:202-211, 1989
167. 167. DECKERT T, FELDT-RASMUSSEN B, DJURUP R, DECKERT M: Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int 33:100-108, 1988
168. 168. DECKERT T, KOFOED-ENEVOLDSEN A, VIDAL P, NORGAARD K, ANDREASEN HB, FELDT-RASMUSSEN B: Size-and charge selectivity of glomerular filtration in type I (insulin-dependent) diabetic patients with and without albuminuria. Diabetolagia 36:244-251, 1993
169. 169. SCANDLING JD, MYERS BD: Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 41:840-846, 1992
170. 170. NAKAMURA Y, MYERS BD: Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 37:1202-1211, 1988
171. 171. PARTHASARATHY N, SPIRO RG: Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 31:738-741, 1982
172. 172. SHIMOMURA H, SPIRO RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36:374-381, 1987
173. 173. MAKINO H, YAMASAKI Y, HARAMOTO T, SHIKATA K, HIRONAKA K, OIA Z, KANWAR YS: Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 68:45-55, 1993
174. 174. NERLICH A, SCHLEICHER E: Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139:889-899, 1991
175. 175. MAKINO H, IKEDA S, HARAMOTO T, OTA Z: Heparan sulfate proteoglycans are lost in patients with diabetic nephropathy. Nephron 61:415-421, 1992
176. 176. SARASWATHI S, VASAN NS: Alterations in the rat renal glycosaminoglycans in streptozotocin-induced diabetes. Biochim Biophys Acta 755:237-243, 1983
177. 177. WU VY, WILSON B, COHEN MP: Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 36:679-683, 1987
178. 178. REDDI AS: Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol 22:323-328, 1991
179. 179. REDDI AS, RAMAMURTHI R, MILLER M, DHUPER S, LASKER N: Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 45:119-131, 1991
180. 180. COHEN MP, KLEPSER H, WU VY: Undersulfation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose reductase inhibition. Diabetes 37:1324-1327, 1988
181. 35S]-labeled glomerular basement membrane. Diabetes 33:8-12, 1984
182. 4 proteoglycans in streptozotocin-induced diabetic rats. Diabetes 35:1130-1142, 1986
183. 183. WARREN J, MASON RM: Steady state measurement of glomerular proteoglycan synthesis in streptozotocin-induced diabetes. Biochem Soc Trans 20:97S, 1992
184. 184. KANWAR YS, ROSENZWEIG LJ, LINKER A, JAKUBOWSKI ML: Decreased de novo synthesis of glomerular proteogiycans in diabetes: Biochemical and autoradiographic evidence. Proc Natl Acad Sci USA 80:2272-2277, 1983
185. 185. COHEN MP, SURMA ML: [(35)S]sulfate incorporation into glomerular basement membrane glycosaminoglycans is decreased in experimental diabetes. J Lab Clin Med 98:715-722, 1981
186. 186. BEAVAN LA, DAVIES M, MASON RM: Renal glomerular proteoglycans: An investigation of their synthesis in vivo using a technique for fixation in situ. Biochem J 251:411-418, 1988
187. 187. VAN DEN BORN J, VAN KRAATS AA, BAKKER MA, ASSMANN KJ, VAN DEN HEUVEL LP, VEERKAMP JH, BERDEN JH: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38:161-172, 1995
188. 188. FUKUI M, NAKAMURA T, EBIHARA I, SHIRATO I, TOMINO Y, KOIDE H: ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 41:1520-1527, 1992
189. 189. LEDBETTER S, COPELAND EJ, NOONAN D, VOGELI G, HASSELL JR: Altered steady-state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition. Diabetes 39:196-203, 1990
190. 190. KOFOED ENEVOLDSEN A, NOONAN D, DECKERT T: Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: Effect of short-term blood glucose control in diabetic rats. Diabetologia 36:310-315, 1993
191. 191. KATO M, WANG H, BERNFIELD M, GALLAGHER JT, TURNBULL JE: Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881-18890, 1994
192. 192. SCHMIDT A, BUDDECKE E: Changes in heparan sulfate structure during transition from the proliferating to the non-dividing state of cultured arterial smooth muscle cells. Eur J Cell Biol 52:229-235, 1990
193. 193. PEJLER G, DAVID G: Basement-membrane heparan sulphate with high affinity for antithrombin synthesized by normal and transformed mouse mammary epithelial cells. Biochem J 248:69-77, 1987
194. 194. IOZZO RV: Presence of unsulfated heparan chains on the heparan sulfate proteoglycan of human colon carcinoma cells: Implications for heparan sulfate proteoglycan biosynthesis. J Biol Chem 264:2690-2699, 1989
195. 195. SAFAIYAN F, LINDAHL U, SALMIVIRTA M: Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem 252:576-582, 1998
196. 196. JAYSON GC, LYON M, PARASKEVA C, TURNBULL JE, DEAKIN JA, GALLAGHER JT: Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 273:51-57, 1998
197. 197. MORRIS SA, WITTNER M, WEISS L, HATCHER VB, TANOWITZ HB, BILEZIKIAN JP, GORDON PB: Extracellular matrix derived from Trypanosoma cruzi infected endothelial cells directs phenotypic expression. J Cell Physiol 145:340-346, 1990
198. 198. FEYZI E, SALDEEN T, LARSSON E, LINDAHL U, SALMIVIRTA M: Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 273:13395-13398, 1998
199. 199. GHISELLI G, LINDAHL U, SALMIVIRTA M: Foam cell conversion of macrophages alters the biosynthesis of heparan sulfate. Biochem Biophys Res Commun 247:790-795, 1998
200. 200. BRICKMAN YG, NURCOMBE V, FORD MD, GALLAGHER JT, BARTLETT PF, TURNBULL JE: Structural comparison of fibroblast growth factor-specific heparan sulfates derived from a growing or differentiating neuroepithelial cell line. Glycobiology 8:463-471, 1998
201. 201. BRICKMAN YG, FORD MD, GALLAGHER JT, NURCOMBE V, BARTLETT PF, TURNBULL JE: Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem 273:4350-4359, 1998
202. 202. JACOBSSON KG, RIESENFELD J, LINDAHL U: Biosynthesis of heparin: Effects of n-butyrate on cultured mast cells. J Biol Chem 260:12154-12159, 1985
203. 203. ZHANG L, SCHWARTZ JJ, MILLER J, LIU J, FRITZE LMS, SCHWORAK NW, ROSENBERG RD: The retinoic acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate biosynthesis in F9 embryonal carcinoma cells. J Biol Chem 273:27998-28003, 1998
204. 204. KAJI T, HIRAGA S, YAMAMOTO C, SAKAMOTO M, NAKASHIMA Y, SUEISHI K, KOIZUMI K: Tumor necrosis factor alpha-induced alteration of glycosaminoglycans in cultured vascular smooth muscle cells. Biochim Biophys Acta 1176:20-26, 1993
205. 205. NISHINAGA M, OZAWA T, SHIMADA K: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:1381-1386, 1993
206. 206. KJELLEN L, BIELEFELD D, HOOK M: Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32:337-342, 1983
207. 207. LEVY P, PICARD J, BRUEL A: Evidence for diabetes-induced alterations in the sulfation of heparin sulfate intestinal epithelial cells. Life Sci 35:2613-2620, 1984
208. 208. SILBIGER S, CROWLEY S, SHAN Z, BROWNLEE M, SATRIANO J, SCHLONDORFF D: Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proleoglycan charge. Kidney Int 43:853-864, 1993
209. 209. SILBIGER S, SCHLONDORFF D, CROWLEY S, ROSENBERG L, CHOI H, HATCHER V, GORDON P: The effect of glucose on proteoglycans produced by cultured mesangial cells. Diabetes 42:1815-1822, 1993
210. 210. VAN DET NF, VAN DEN BORN J, TAMSMA JT, VERHAGEN NA, BERDEN JHM, BRUIJN JA, DAHA MR, VAN DEN WOUDE FJ: Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int 49:1079-1089, 1996
211. 211. VAN DET NF, TAMSMA JT, VAN DEN BORN J, VERHAGEN NA, VAN DEN HEUVEL LP, LOWIK CW, BERDEN JH, BRUIJN JA, DAHA MR, VAN DER WOUDE FJ: Differential effects of angiotensin II and transforming growth factor beta on the production of heparan sulfate protcoglycan by mesangial cells in vitro. J Am Soc Nephrol 7:1015-1023, 1996
212. 212. UNGER E, PETTERSON I, ERIKSSON UJ, LINDAHL U, KJELLEN L: Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. J Biol Chem 266:8671-8674, 1991
213. 213. KOFOED ENEVOLDSEN A: Inhibition of glomerular glucosaminyl N-deacetylase in diabetic rats. Kidney Int 41:763-767, 1992
214. 214. DECKERT T, FELDT RASMUSSEN B, BORCH JOHNSEN K, JENSEN T, KOFOED ENEVOLDSEN A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. Diabetologia 32:219-226, 1989
215. 215. YOKOYAMA H, HOYLER PE, HANSEN PM, VAN DEN BORN J, JENSEN T, BERDEN JH, DECKERT T, GARBARSCH C: Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Diabetes 46:1875-1880, 1997
216. 216. VAN DER PIJL JW, DAHA MR, VAN DEN BORN J, VERHAGEN NA, LEMKES HH, BUCALA R, BERDEN JH, ZWINDERMAN AH, BRUIJN JA, VAN ES LA, VAN DER WOUDE FJ: Extracellular matrix in human diabelic nephropathy: Reduced expression of heparan sulphate in skin basement membrane. Diabetologia 41:791-798, 1998
217. 217. VAN DEN BORN J, VAN KRAATS AA, HILL S, BAKKER MA, BERDEN JH: Vessel wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in the rat. Nephrol Dial Transplant 12(Suppl 2):27-31, 1997
218. 218. LELONGT B, MAKINO H, KANWAR YS: Status of glomerular proteoglycans in aminonucleoside nephrosis. Kidney Int 31:1299-1310, 1987
219. 219. GROGGEL GC, STEVENSON J, HOVINGH P, LINKER A, BORDER WA: Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int 33:517-523, 1988
220. 220. VAN KUPPEVELT TH, DENNISSEN MABA, VAN VENROOIJ WJ, HOTT RMA, VEERKAMP JH: Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273:12960-12966, 1998